Alexander E. Tseimakh

Alexander E. Tseimakh

Auto-generated profile, based on publicly available information

Alexander E. Tseimakh

Altai State Medical University, Barnaul

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Bulletin of Medical Science
Verified
Journal Article
Open access
PDF file
ATAlexander E. Tseimakh
Alexander E. Tseimakh
SSSergey G. Shtofin
Sergey G. Shtofin
YSYakov N. Shoikhet
Yakov N. Shoikhet
ETEvgeny A. Tseimakh
Evgeny A. Tseimakh
Бюллетень медицинской науки Журнал «Бюллетень медицинской науки» Журнал АГМУ «Бюллетень медицинской науки» — это электронный научно-практический медицинский рецензируемый журнал Алтайского государственного медицинского университета. Журнал публикует оригинальные исследования, описания клинических случаев, научные обзоры и дискуссии.

23 April 2020 in Biomedical Photonics
Verified
Journal Article
Open access
PDF file
ATA. E. Tseimakh
A. E. Tseimakh
ALA. F. Lazarev
A. F. Lazarev
ESE. L. Sekerzhinskaya
E. L. Sekerzhinskaya
VKV. A. Kurtukov
V. A. Kurtukov
AMA. N. Mitshenko
A. N. Mitshenko
YSYa. N. Shoykhet
Ya. N. Shoykhet
В работе представлены результаты комплексного паллиативного лечения с применением фотодинамической терапии (ФДТ) больных со злокачественными новообразованиями (ЗНО) панкреатобилиарной зоны, осложненными механической желтухой. В основной группе, включавшей 22 больных, было проведено паллиативное комплексное лечение с применением локальной и системной ФДТ новообразований панкреатобилиарной зоны, осложненных механической желтухой. В группе сравнения, состоявшей из 165 больных, было проведено паллиативное комплексное лечение осложнений без применения ФДТ. В качестве фотосенсибилизатора использовали препараты хлоринового ряда: фотодитазин (у 21 пациента) и радахлорин (1 пациент). Первым этапом проводили системную ФДТ. В процессе инфузии через периферический доступ в кубитальную вену надвенно проводили лазерное облучение крови монохроматическим светом с длиной волны 662–665 нм и световой дозой 1200–1400 Дж/см2 . По истечении 3–5 ч с момента окончания инфузии вторым этапом осуществлялась локальная внутрипротоковая ФДТ путем облучения монохроматическим светом с длиной волны 662 нм и дозой света 220 Дж/см2 . На фоне применения локальной и системной ФДТ в основной группе в течение недели после лечения установлено статистически значимое уменьшение размеров опухолевого очага у больных с ЗНО поджелудочной железы по данным ультразвукового исследования брюшной полости, отмечено восстановление выведения желчи в кишечник у 100% больных с ЗНО желчевыводящих протоков и головки поджелудочной железы. Установлено увеличение медианы выживаемости пациентов опытной группы до 5,9 мес по сравнению с 4,7 мес в контрольной группе.

6 May 2020 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
ITI. Ya. Tseymakh
I. Ya. Tseymakh
YSYa. N. Shoykhet
Ya. N. Shoykhet
ATA. E. Tseymakh
A. E. Tseymakh
The objective: to study the effect of sleep-related breathing disorders on the activation of blood coagulation reactions associated with systemic inflammation in patients with chronic obstructive pulmonary disease and concurrent obstructive sleep apnea.Subjects and methods. An open prospective comparative study analyzed thrombogenic risk factors, markers of inflammation and insulin resistance in 65 patients with chronic obstructive pulmonary disease and concurrent obstructive sleep apnea, 26 of them received non-invasive ventilation as a part of their therapy (main group).Results. The blood levels of homocysteine and prothrombin fragments 1+2 are closely associated with the duration of nocturnal hypoxemia, concentrations of C-reactive protein, C-peptide, and endothelial vascular growth factor and can be managed with CPAP therapy.The authors state that they have no conflict of interests.

14 October 2023 in Russian Journal of Oncology
Verified
Journal Article
Open access
PDF file
ATA. Е. Tseimakh
A. Е. Tseimakh
АЛА. Ф. Лазарев
А. Ф. Лазарев
YSY. N. Shoykhet
Y. N. Shoykhet
Pancreatic cancer is one of the most serious problems of modern oncology. In the Russian Federation, pancreatic cancer, along with a fairly small share in the structure of the incidence of malignant neoplasms 3%, ranks first in annual mortality (68.2%), and is also a nosology with the most unfavorable prognosis among tumors of the gastrointestinal tract. The current standard of first-line therapy is FOLFRINOX (FOLFIRINOX, a combination of 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin) or gemcitabine plus albumin-bound nab-paclitaxel. One of the main obstacles to the action of chemotherapeutic drugs is the microenvironment of fibro-solid stromal tumors, which include pancreatic cancer. In order to potentiate the action of chemotherapy and combat the tumor microenvironment, at the present stage, drugs are being considered for influencing the programmed death 1 (PD-1) gene and cytotoxic T-lymphocyte antigen 4 (CTLA-4). Approximately 1015% of malignant neoplasms of the pancreas are believed to be associated with hereditary mutations, while all neoplasms have somatic mutations in different combinations of driver genes. One of the most common mutations are BRCA1/BRCA2 gene mutations. Poly-ADP-ribose polymerase inhibitors, like cisplatin, have shown promise as a treatment for tumors with BRCA mutations. Another subtype of pancreatic cancer is characterized by microsatellite instability. Unlike the above mutations and phenotypes, which affect only a small proportion of patients with pancreatic cancer, mutations in KRAS (Kirsten homologous rat sarcoma viral oncogene) are found in 9095% of cases of pancreatic malignancy and may be a significant factor in pancreatic tumorigenesis. Another frequently mutating gene for a number of malignancies is ARID1A, which encodes a tumor suppressor protein, a subunit of the SWI/SNF chromatin remodeling complex. The future of conservative therapy for pancreatic cancer is a complex treatment that includes both chemotherapy and targeted therapy and immunotherapy, the implementation of which is impossible without a deeper study of genetic mutations, molecular mechanisms of invasion and development of pancreatic malignant neoplasms, as well as extensive testing for genetic mutations in the clinical practice of specialized institutions.

3 April 2023 in Bulletin physiology and pathology of respiration
Verified
Journal Article
Open access
PDF file
ITI. Ya. Tseimakh
I. Ya. Tseimakh
DBD. E. Bogachev
D. E. Bogachev
GKG. I. Kostuchenko
G. I. Kostuchenko
AMA. N. Mamaev
A. N. Mamaev
TKT. A. Kornilova
T. A. Kornilova
ЯШЯ. Н. Шойхет
Я. Н. Шойхет
Aim. To assess the effect of serum homocysteine levels on treatment outcomes in patients with COVID19-associated lung damage, depending on the use of folic acid in complex treatment.Materials and methods. An open, prospective comparative study included 71 hospitalized adult patients with COVID-19-associated lung disease who did not require mechanical ventilation. The main group included 51 patients who received folic acid 15 mg per day in a complex treatment in a fixed combination with pyridoxine hydrochloride and cyanocobalamin. The comparison group included 20 patients in whose therapy folic acid was not used.Results. The use of folic acid was accompanied by a decrease in serum homocysteine concentration by 2.120 (-0.230; 3.680) µmol/L (p=0.004). When constructing a logistic regression model, the effect of a decrease in serum homocysteine (OR 1.289; 95% CI 1.026‒1.620; p=0.029), methylenetetrahydrofolate reductase MTHFR C677T genotype (OR 10.897; 95% CI 1.240‒95.772; p=0.031) on the achievement of 7th day of hospitalization, the cessation of isolation of SARS-CoV-2 virus RNA from the respiratory tract. Multiple linear regression analysis showed an association between the duration of hypoxemic respiratory failure, determined with SaO2≤93%, with the degree of change in serum homocysteine concentration after treatment, single nucleotide polymorphisms of methylenetetrahydrofolate reductase MTHFR C677T, methionine synthase MTR A2756G and methionine synthase reductase MTRR A66G, initial volume of lung damage ≥50% according to CT data, indicators of D-dimers, C-reactive protein, hemoglobin, platelets, concomitant hypertension, diabetes mellitus (R=0.699; R2=0.489; p=0.005).Conclusion. The dynamics of the decrease in serum homocysteine after treatment is an important predictor of the cessation of isolation from the respiratory tract of the SARS-CoV-2 virus RNA on the 7th day of treatment, reducing the duration of hypoxemic respiratory failure in patients with lung damage associated with COVID-19 infection.

19 March 2023 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Open access
PDF file
ATA. E. Tseimakh
A. E. Tseimakh
VKV. A. Kurtukov
V. A. Kurtukov
VTV. N. Tepluhin
V. N. Tepluhin
YSY. N. Shoikhet
Y. N. Shoikhet
ЯШЯ. Н. Шойхет
Я. Н. Шойхет
The paper presents clinical observation of a patient with cholelithiasis and so-called “difficult” choledocholithiasis. Considering the developed complications – mechanical jaundice and purulent cholangitis, as well as large operative risk, it was decided to refrain from open surgical intervention. Traditionally-performed endoscopic stone extraction did not provide any success. Contact electro-impulse lithotripsy and lithotomy were performed. This enabled choledocholithiasis and cholangitis to be eliminated, bile ducts patency to be restored, and ensured the possibility of safe elective surgical intervention for chronic calculous cholecystitis.